Relay Therapeutics (RLAY) Chief Corporate Development Officer Peter Rahmer Sells Shares

What Happened
Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics (RLAY), sold 748 shares in an open-market transaction on July 28, 2026 at $18.61 per share, generating proceeds of about $13,920. The sale was executed to satisfy income tax withholding obligations tied to the vesting of RSUs.

Key Details

• Transaction date: July 28, 2026; filing date: July 30, 2026 (Form 4 accession 0001193125-26-326142). Filing appears timely.
• Sale details: 748 shares sold at $18.61 per share for total proceeds reported as $13,920. (Transaction code S = Sale.)
• Reason: Footnote states the sale was to cover tax withholding upon vesting of 3,051 RSUs on July 27, 2026; the reporting person had no discretion over the sale and it complied with the issuer’s RSU-vesting policies. (Tax-withholding transaction.)
• Holdings note: Filing indicates beneficial ownership includes 6,102 shares underlying RSUs.
• Role: Reporting person is the Chief Corporate Development Officer.

Context
This was a routine, non-discretionary sale to satisfy tax withholding tied to RSU vesting, not an open-market investment decision. Such withholding sales are common and generally not considered a strong signal of insider sentiment about the company’s prospects.